---
document_datetime: 2023-09-21 18:45:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/inductos-epar-procedural-steps-taken-authorisation_en.pdf
document_name: inductos-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3782169
conversion_datetime: 2025-12-31 04:54:01.453733
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Genetics Institute of Europe B.V. (Germany) submitted on 9 March 2001 an application for  Marketing  Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products (EMEA) for InductOs, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr. Barbara van Zwieten-Boot Co-Rapporteur:

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 16 March 2001.
- The Rapporteur's first Assessment Report was circulated to all CPMP  members  on 12  June  2001.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 4 June 2001.
- During the meeting on 24-26 July 2001 the CPMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 26 July 2001.
- The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 13 November 2001.
- The  summary  report  of  the  inspection  carried  out  at  the  Integra  LifeSciences  Corporation manufacturing site (manufacturer of the absorbable collagen sponge) between 22-24 January 2002, and of 10-11 April 2002 (follow-up inspection) by the MCA was issued on 10 May 2002.
- The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 15 January 2002.
- During the meeting on 11-13 February 2002, the BWP discussed the outstanding quality issues. A report to the CPMP was prepared.
- During the CPMP meeting on 19-21 February 2002 the CPMP adopted a list of questions to be addressed during an oral explanation.
- During the CPMP meeting of 23-25 April 2002, the CPMP agreed that there was no need for an oral explanation. A list of outstanding issues to be addressed in writing prior to the opinion was issued.
- The company submitted answers to the outstanding quality  questions  on  18  April  2002.  The Rapporteur circulated an assessment report of these answers to all CPMP members on 17 May 2002.
- The company submitted written responses to the Part IV-Clinical/SPC issues on 22 May 2002.
- During the meeting on 21-23 May 2002 the BWP discussed the responses on the outstanding quality questions, and prepared a final report to the CPMP.
- During the meeting on 28-30 May 2002 the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to InductOs on 30 May 2002.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 9 September 2002.

Dr. Markku Toivonen